NVO - Novo Nordisk - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

582.8B

Cash

9.303B

Avg Qtr Burn

N/A

Short % of Float

0.10%

Insider Ownership

0.00%

Institutional Own.

9.76%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Once-weekly basal insulin icodec Details Diabetes mellitus , Type 1 diabetes	BLA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CagriSema Details Obesity, Type 2 diabetes	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cagrilintide + Semaglutide Details Obesity	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etavopivat (FT-4202) (PKR activator) Details Sickle cell disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT-7051 (CBP/P300 inhibitor) Details Castration-resistant prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.